Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

Publisher： Karger

E-ISSN： 2296-5262|39|6|384-387

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.6, 2016-05, pp. : 384-387

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Improvement in Hematopoiesis after Iron Chelation Therapy with Deferasirox in Patients with Aplastic Anemia

By  

Acta Haematologica, Vol. 129, Iss. 2, 2012-11 ,pp. : 72-77

Karger

Access to resources Recommend Favorite

Loss of Transfusion Dependency Following Deferasirox Treatment of Iron Overload in a Woman with Myelofibrosis and Spherocytosis - a Case Report

By  

Oncology Research and Treatment, Vol. 36, Iss. 4, 2013-03 ,pp. : 205-208

Karger

Access to resources Recommend Favorite

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

By  

Acta Haematologica, Vol. 120, Iss. 2, 2008-10 ,pp. : 70-74

Karger

Access to resources Recommend Favorite

Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia

By  

Acta Haematologica, Vol. 137, Iss. 1, 2016-11 ,pp. : 20-26

Karger

Access to resources Recommend Favorite